ION expands ETF trading capabilities with Tradeweb integration
Director Arani Bose of Penumbra Inc (NASDAQ:PEN) sold 7,500 shares of common stock on November 21, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed in two transactions at weighted average prices of $290.55 and $291.09, resulting in total proceeds of approximately $2.17 million. The stock is currently trading at $298.71, near its 52-week high of $310, and has gained 25.78% year-to-date. According to InvestingPro analysis, Penumbra appears overvalued compared to its Fair Value.
The first sale involved 7,338 shares sold at prices ranging from $290.00 to $290.97. The second sale consisted of 162 shares sold at prices ranging from $291.09 to $291.13.
Following the transactions, Bose directly owns 558 shares of Penumbra. Additionally, Bose indirectly owns 282,761 shares through Bose Family Holdings II, LLC.
The sales were conducted under a pre-arranged Rule 10b5-1 trading plan.
In other recent news, Penumbra reported impressive third-quarter 2025 financial results, with revenue reaching $354.7 million, marking a 17.8% year-over-year increase and surpassing the forecast of $340.91 million. This strong performance led the company to raise its 2025 revenue guidance. Analysts responded positively to these results, with Needham reiterating its Buy rating and setting a price target of $326.00. Truist Securities also maintained a Buy rating, raising its price target to $312.00 due to strong growth in the venous thromboembolism segment. Evercore ISI adjusted its price target slightly to $286.00, noting the company’s 17% organic revenue growth and significant performance in the Embolization segment. Penumbra’s U.S. Embolization & Access segment outperformed expectations, contributing to a 3.5% revenue beat. Additionally, the U.S. Thrombectomy segment saw a 19% revenue increase, aligning with forecasts. These developments underscore Penumbra’s solid market position and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.